The purpose of this study is to consider the following points in patients with hypertension who complicated by metabolic syndrome for Valsartan basis treatment and an existing, standard treatment.

• Blood pressure control
• Changing of adiponectin and plasminogen activator inhibitor-1
• Influence metabolizing and cardiac function, etc.

The primary endpoints are:

• blood pressure control
• Adiponectin and plasma type1 plasminogen active inhibitor

The secondary endpoints are

• HOMA-IR
• HbA1c
• TNF-α
• IL-6
• Plasma B-type natriuretic peptide
• LVMI
• E/A ratio
• Tei-index
• Apo-J

Inclusion Criteria:

• Out patients with hypertension male and female
• Systolic blood pressure (SBP)≧140mmHg and/or diastolic blood pressure (DBP)≧90 mmHg
• Waist Surrounding diameter male≧85cm female≧90cm
• Patient who is treating either high triglyceride,low HDL,or diabetes mellitus
• Patient who is untreatment high triglyceride blood syndrome and low HDL blood syndrome,diabetes mellitus is triglceride≧150mg/dl and/or HDL cholesterol < 40 mg/dl or fasting blood glucose ≧110 mg/dl
• Untreated patients with hypertension,or patients is treated with antihypertensive agents except for ACE-I and ARB

Exclusion Criteria:

• Patient who is using ACE-I and ARB
• Serum creatinine ≧ 3 mg/dl
• Liver impairment
• History of allergy to valsartan
• Pregnant women
• Judgment by the physician that participation was unwise on the basis of patient characteristics and drug safety